Intrinsic value of VBI Vaccines, Inc. - VBIV

Previous Close

$1.01

  Intrinsic Value

$0.08

stock screener

  Rating & Target

str. sell

-92%

Previous close

$1.01

 
Intrinsic value

$0.08

 
Up/down potential

-92%

 
Rating

str. sell

We calculate the intrinsic value of VBIV stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  5
  7
  11
  16
  23
  31
  42
  55
  71
  89
  111
  136
  164
  195
  229
  266
  307
  350
  397
  446
  498
  553
  610
  671
  734
  799
  868
  939
  1,013
  1,090
Variable operating expenses, $m
  54
  79
  115
  164
  228
  312
  416
  544
  698
  880
  1,084
  1,326
  1,598
  1,901
  2,236
  2,600
  2,995
  3,420
  3,873
  4,355
  4,864
  5,400
  5,962
  6,551
  7,166
  7,807
  8,475
  9,170
  9,892
  10,643
Fixed operating expenses, $m
  30
  30
  31
  32
  32
  33
  34
  35
  35
  36
  37
  38
  38
  39
  40
  41
  42
  43
  44
  45
  46
  47
  48
  49
  50
  51
  52
  53
  55
  56
Total operating expenses, $m
  84
  109
  146
  196
  260
  345
  450
  579
  733
  916
  1,121
  1,364
  1,636
  1,940
  2,276
  2,641
  3,037
  3,463
  3,917
  4,400
  4,910
  5,447
  6,010
  6,600
  7,216
  7,858
  8,527
  9,223
  9,947
  10,699
Operating income, $m
  -78
  -102
  -135
  -179
  -238
  -313
  -408
  -523
  -663
  -827
  -1,010
  -1,228
  -1,473
  -1,746
  -2,047
  -2,375
  -2,731
  -3,113
  -3,521
  -3,954
  -4,412
  -4,894
  -5,399
  -5,929
  -6,482
  -7,059
  -7,659
  -8,284
  -8,934
  -9,609
EBITDA, $m
  -70
  -92
  -123
  -166
  -221
  -293
  -382
  -492
  -624
  -780
  -961
  -1,167
  -1,400
  -1,659
  -1,945
  -2,257
  -2,594
  -2,957
  -3,344
  -3,755
  -4,190
  -4,647
  -5,128
  -5,630
  -6,155
  -6,703
  -7,273
  -7,866
  -8,482
  -9,123
Interest expense (income), $m
  0
  3
  7
  14
  23
  35
  51
  72
  98
  131
  170
  216
  269
  330
  398
  475
  559
  651
  751
  858
  972
  1,094
  1,222
  1,357
  1,499
  1,648
  1,803
  1,965
  2,133
  2,308
  2,491
Earnings before tax, $m
  -81
  -109
  -148
  -202
  -273
  -365
  -480
  -622
  -793
  -996
  -1,226
  -1,496
  -1,803
  -2,144
  -2,522
  -2,934
  -3,382
  -3,864
  -4,379
  -4,926
  -5,505
  -6,116
  -6,757
  -7,428
  -8,130
  -8,862
  -9,624
  -10,417
  -11,242
  -12,099
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -81
  -109
  -148
  -202
  -273
  -365
  -480
  -622
  -793
  -996
  -1,226
  -1,496
  -1,803
  -2,144
  -2,522
  -2,934
  -3,382
  -3,864
  -4,379
  -4,926
  -5,505
  -6,116
  -6,757
  -7,428
  -8,130
  -8,862
  -9,624
  -10,417
  -11,242
  -12,099

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  160
  247
  370
  536
  757
  1,040
  1,397
  1,834
  2,360
  2,980
  3,701
  4,525
  5,454
  6,489
  7,630
  8,875
  10,224
  11,672
  13,220
  14,863
  16,600
  18,429
  20,348
  22,358
  24,456
  26,645
  28,924
  31,295
  33,761
  36,323
Adjusted assets (=assets-cash), $m
  160
  247
  370
  536
  757
  1,040
  1,397
  1,834
  2,360
  2,980
  3,701
  4,525
  5,454
  6,489
  7,630
  8,875
  10,224
  11,672
  13,220
  14,863
  16,600
  18,429
  20,348
  22,358
  24,456
  26,645
  28,924
  31,295
  33,761
  36,323
Revenue / Adjusted assets
  0.031
  0.028
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
  0.030
Average production assets, $m
  64
  99
  148
  215
  303
  417
  560
  735
  946
  1,195
  1,484
  1,814
  2,187
  2,602
  3,059
  3,558
  4,099
  4,680
  5,300
  5,959
  6,655
  7,388
  8,158
  8,964
  9,805
  10,682
  11,596
  12,547
  13,535
  14,563
Working capital, $m
  -32
  -49
  -73
  -106
  -150
  -206
  -277
  -363
  -468
  -591
  -733
  -897
  -1,081
  -1,286
  -1,512
  -1,759
  -2,026
  -2,313
  -2,619
  -2,945
  -3,289
  -3,652
  -4,032
  -4,430
  -4,846
  -5,280
  -5,731
  -6,201
  -6,690
  -7,197
Total debt, $m
  37
  70
  117
  180
  264
  372
  508
  674
  875
  1,111
  1,386
  1,700
  2,054
  2,448
  2,883
  3,357
  3,871
  4,423
  5,012
  5,638
  6,300
  6,997
  7,728
  8,494
  9,294
  10,127
  10,996
  11,899
  12,839
  13,815
Total liabilities, $m
  61
  94
  141
  204
  288
  396
  532
  699
  899
  1,135
  1,410
  1,724
  2,078
  2,472
  2,907
  3,381
  3,895
  4,447
  5,037
  5,663
  6,325
  7,021
  7,753
  8,518
  9,318
  10,152
  11,020
  11,923
  12,863
  13,839
Total equity, $m
  99
  153
  229
  332
  468
  644
  864
  1,135
  1,461
  1,845
  2,291
  2,801
  3,376
  4,017
  4,723
  5,494
  6,328
  7,225
  8,183
  9,200
  10,275
  11,407
  12,596
  13,839
  15,139
  16,493
  17,904
  19,372
  20,898
  22,484
Total liabilities and equity, $m
  160
  247
  370
  536
  756
  1,040
  1,396
  1,834
  2,360
  2,980
  3,701
  4,525
  5,454
  6,489
  7,630
  8,875
  10,223
  11,672
  13,220
  14,863
  16,600
  18,428
  20,349
  22,357
  24,457
  26,645
  28,924
  31,295
  33,761
  36,323
Debt-to-equity ratio
  0.370
  0.460
  0.510
  0.540
  0.560
  0.580
  0.590
  0.590
  0.600
  0.600
  0.600
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
  0.610
Adjusted equity ratio
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619
  0.619

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -81
  -109
  -148
  -202
  -273
  -365
  -480
  -622
  -793
  -996
  -1,226
  -1,496
  -1,803
  -2,144
  -2,522
  -2,934
  -3,382
  -3,864
  -4,379
  -4,926
  -5,505
  -6,116
  -6,757
  -7,428
  -8,130
  -8,862
  -9,624
  -10,417
  -11,242
  -12,099
Depreciation, amort., depletion, $m
  9
  10
  12
  14
  17
  21
  25
  31
  38
  47
  49
  60
  73
  87
  102
  119
  137
  156
  177
  199
  222
  246
  272
  299
  327
  356
  387
  418
  451
  485
Funds from operations, $m
  -72
  -99
  -137
  -188
  -256
  -344
  -455
  -591
  -755
  -950
  -1,176
  -1,436
  -1,730
  -2,058
  -2,420
  -2,816
  -3,245
  -3,708
  -4,202
  -4,728
  -5,284
  -5,870
  -6,485
  -7,129
  -7,803
  -8,506
  -9,237
  -9,999
  -10,791
  -11,614
Change in working capital, $m
  -12
  -17
  -24
  -33
  -44
  -56
  -71
  -87
  -104
  -123
  -143
  -163
  -184
  -205
  -226
  -247
  -267
  -287
  -307
  -326
  -344
  -362
  -380
  -398
  -416
  -434
  -452
  -470
  -489
  -508
Cash from operations, $m
  -60
  -82
  -113
  -155
  -213
  -288
  -384
  -504
  -651
  -827
  -1,033
  -1,273
  -1,546
  -1,852
  -2,194
  -2,569
  -2,978
  -3,421
  -3,895
  -4,402
  -4,939
  -5,507
  -6,105
  -6,731
  -7,387
  -8,072
  -8,786
  -9,529
  -10,302
  -11,106
Maintenance CAPEX, $m
  -1
  -2
  -3
  -5
  -7
  -10
  -14
  -19
  -25
  -32
  -40
  -49
  -60
  -73
  -87
  -102
  -119
  -137
  -156
  -177
  -199
  -222
  -246
  -272
  -299
  -327
  -356
  -387
  -418
  -451
New CAPEX, $m
  -24
  -35
  -49
  -67
  -88
  -114
  -143
  -175
  -211
  -249
  -289
  -330
  -372
  -415
  -457
  -499
  -541
  -581
  -620
  -659
  -696
  -733
  -770
  -806
  -841
  -877
  -914
  -951
  -988
  -1,027
Cash from investing activities, $m
  -25
  -37
  -52
  -72
  -95
  -124
  -157
  -194
  -236
  -281
  -329
  -379
  -432
  -488
  -544
  -601
  -660
  -718
  -776
  -836
  -895
  -955
  -1,016
  -1,078
  -1,140
  -1,204
  -1,270
  -1,338
  -1,406
  -1,478
Free cash flow, $m
  -86
  -119
  -165
  -227
  -308
  -412
  -541
  -698
  -886
  -1,107
  -1,362
  -1,652
  -1,978
  -2,340
  -2,738
  -3,170
  -3,637
  -4,138
  -4,672
  -5,237
  -5,834
  -6,462
  -7,120
  -7,809
  -8,527
  -9,276
  -10,056
  -10,866
  -11,709
  -12,585
Issuance/(repayment) of debt, $m
  23
  33
  47
  64
  84
  108
  136
  167
  200
  237
  275
  314
  354
  394
  435
  475
  514
  552
  589
  626
  662
  697
  731
  766
  800
  834
  868
  903
  939
  976
Issuance/(repurchase) of shares, $m
  118
  163
  224
  305
  409
  540
  700
  893
  1,119
  1,380
  1,672
  2,006
  2,378
  2,785
  3,228
  3,705
  4,217
  4,761
  5,336
  5,943
  6,581
  7,248
  7,945
  8,672
  9,429
  10,216
  11,035
  11,885
  12,768
  13,686
Cash from financing (excl. dividends), $m  
  141
  196
  271
  369
  493
  648
  836
  1,060
  1,319
  1,617
  1,947
  2,320
  2,732
  3,179
  3,663
  4,180
  4,731
  5,313
  5,925
  6,569
  7,243
  7,945
  8,676
  9,438
  10,229
  11,050
  11,903
  12,788
  13,707
  14,662
Total cash flow (excl. dividends), $m
  55
  77
  106
  142
  185
  237
  295
  361
  433
  510
  584
  668
  753
  839
  925
  1,010
  1,093
  1,174
  1,254
  1,332
  1,408
  1,483
  1,556
  1,629
  1,701
  1,774
  1,847
  1,922
  1,999
  2,077
Retained Cash Flow (-), $m
  -118
  -163
  -224
  -305
  -409
  -540
  -700
  -893
  -1,119
  -1,380
  -1,672
  -2,006
  -2,378
  -2,785
  -3,228
  -3,705
  -4,217
  -4,761
  -5,336
  -5,943
  -6,581
  -7,248
  -7,945
  -8,672
  -9,429
  -10,216
  -11,035
  -11,885
  -12,768
  -13,686
Prev. year cash balance distribution, $m
  36
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -27
  -86
  -118
  -163
  -224
  -304
  -405
  -532
  -686
  -871
  -1,088
  -1,339
  -1,625
  -1,946
  -2,303
  -2,696
  -3,124
  -3,586
  -4,082
  -4,611
  -5,173
  -5,765
  -6,389
  -7,043
  -7,728
  -8,442
  -9,187
  -9,963
  -10,770
  -11,608
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -26
  -78
  -103
  -135
  -174
  -220
  -274
  -332
  -394
  -456
  -517
  -571
  -618
  -653
  -676
  -685
  -680
  -660
  -629
  -586
  -535
  -478
  -419
  -359
  -301
  -246
  -197
  -154
  -118
  -87
Current shareholders' claim on cash, %
  34.7
  13.1
  5.3
  2.3
  1.0
  0.5
  0.2
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccine candidates and novel technology platforms in Israel and internationally. It develops products based on eVLP, a platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccines platform, a proprietary formulation and process that allow vaccines and biologics to preserve stability, potency, and safety. The company’s commercial stage product is Sci-B-Vac, a third-generation licensed hepatitis B vaccine for adults, children, and newborn infants. It is also involved in CMV vaccine program, which is in Phase I clinical trials for the prevention of cytomegalovirus infection; GBM immunotherapy program, a preclinical stage glioblastoma multiforme therapeutic vaccine candidate; and RSV vaccine program, a discovery stage novel respiratory syncytial virus vaccine candidate. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

FINANCIAL RATIOS  of  VBI Vaccines, Inc. (VBIV)

Valuation Ratios
P/E Ratio 0
Price to Sales 0
Price to Book 0
Price to Tangible Book
Price to Cash Flow 0
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio NaN
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 0%
Ret/ On Assets - 3 Yr. Avg. 0%
Return On Total Capital 0%
Ret/ On T. Cap. - 3 Yr. Avg. 0%
Return On Equity 0%
Return On Equity - 3 Yr. Avg. 0%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

VBIV stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the VBIV stock intrinsic value calculation we used $3 million for the last fiscal year's total revenue generated by VBI Vaccines, Inc.. The default revenue input number comes from 0001 income statement of VBI Vaccines, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our VBIV stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for VBIV is calculated based on our internal credit rating of VBI Vaccines, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of VBI Vaccines, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of VBIV stock the variable cost ratio is equal to 1200%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $29 million in the base year in the intrinsic value calculation for VBIV stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 19.4% for VBI Vaccines, Inc..

Corporate tax rate of 27% is the nominal tax rate for VBI Vaccines, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the VBIV stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for VBIV are equal to 1336.4%.

Life of production assets of 138 years is the average useful life of capital assets used in VBI Vaccines, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for VBIV is equal to -660.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $98.133 million for VBI Vaccines, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 97.660 million for VBI Vaccines, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of VBI Vaccines, Inc. at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
CDE Coeur Mining, 4.19 1.05  str.sell
RGLD Royal Gold, In 99.11 12.45  str.sell

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.